Stockreport

MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

MacroGenics, Inc.  (MGNX) 
Last macrogenics, inc. earnings: 11/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.macrogenics.com
PDF Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy)Oral abstrac [Read more]